Fluorine-18–labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL)

Autor: Wong, Lih-Ming, Sutherland, Tom, Perry, Elisa, Tran, Vy, Spelman, Tim, Corcoran, Niall, Lawrentschuk, Nathan, Woo, Henry, Lenaghan, Daniel, Buchan, Nicholas, Bax, Kevin, Symons, James, Saeed Goolam, Ahmed, Chalasani, Venu, Hegarty, Justin, Thomas, Lauren, Christov, Alexandar, Ng, Michael, Khanani, Hadia, Lee, Su-faye, Taubman, Kim, Tarlinton, Lisa
Zdroj: European Urology Oncology; October 2024, Vol. 7 Issue: 5 p1015-1023, 9p
Abstrakt: Multiparametric magnetic resonance imaging (mpMRI) remains better than prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) for detecting cancer within the prostate. A combination of the two imaging modalities, with exceptionally high negative predictive value, could help patients avoid prostate biopsy. PSMA-PET/CT should be considered for diagnostic use in patients unable to have mpMRI or as a second-line investigation for those with concerning clinical features but negative mpMRI.
Databáze: Supplemental Index